A Synthetic Route to 2-Alkyl Indoles via Thiophenol-Mediated Ring-Opening of *N*-Tosylaziridines Followed by Copper Powder-Mediated C–N Cyclization/Aromatization

Masthanvali Sayyad, Yerramsetti Nanaji, and Manas K. Ghorai*

Department of Chemistry, Indian Institute of Technology, Kanpur 208016, India

Supporting Information

ABSTRACT: A simple strategy for the syntheses of 2-alkyl indoles via regioselective ring-opening of 2-(2-haloaryl)-3-alkyl-*N*-tosylaziridines with thiophenol, followed by copper powder-mediated intramolecular C–N cyclization and subsequent aromatization by the elimination of thiophenol, with good yields is described. Utilizing this protocol, 2-carbox-yindole has been synthesized easily.

ndoles are one of the most valuable and hence desired heterocyclic scaffolds in organic and medicinal chemistry. To date, more than 4000 indole alkaloids have been isolated from different natural sources; many of them are of immense biological, pharmacological, and synthetic importance.¹ Some of the natural products and other commercial drug molecules containing an indole skeleton as the key molecular framework, e.g., Birnbaumin A, Meridianin C, Apaziquone, Indomethacin, Fluvastatin, etc., are shown in Figure 1. Because of the biological relevance and chemical versatility of indole heterocycles, development of their practical synthetic routes has been extensively explored over the years.² Although the classical "Fischer indole synthesis" is a unique method for the large-scale production of a variety of indoles,³ a number of other interesting protocols based on metal catalysis were introduced in the literature.^{4,5} Although 2-alkyl indoles can be easily obtained via alpha lithiation of indoles,^{5e} it is difficult to make halogenated 2-alkyl indoles via the same route. In this context, an interesting protocol to 2-alkyl indoles via Pd-catalyzed C-H activation of indole has recently been developed by Bach et al.⁵ Although the synthesis of indoles from azirines is well-known,⁶ to the best of our knowledge, no such synthetic route to indoles from aziridines has been reported in the literature so far. Recently, we have developed a simple route for the synthesis of 3-heteroatom substituted-indolines via ring-opening of 2-(2haloaryl)-N-tosylaziridines with various heteroatomic nucleophiles including thiophenol, followed by C-N cyclization.⁷ Inspired by our results, we envisioned that 2-substituted indoles can easily be synthesized from the ring-opening of 2-(2haloaryl)-N-activated aziridines with thiophenol, followed by metal-catalyzed C-N cyclization and simultaneous aromatization via elimination of thiophenol. Several interesting strategies are known for the ring-opening of aziridines with sulfur atomic nucleophiles⁸ and other nucleophiles.⁹ In recent time, coppercatalyzed C-N cyclization has become a powerful tool in organic synthesis.^{8h,10,11} In continuation of our research activities in this area, we have developed a simple and



straightforward strategy for the synthesis of 2-substituted indoles via S_N 2-type ring-opening of 2-(2-haloaryl)-*N*-activated aziridines with thiophenol, followed by Cu-mediated C–N cyclization/aromatization (Scheme 1). Herein, we report our results as a Note.

To realize our idea, initially, we studied the reaction of 2-(2-bromophenyl)-1-tosylaziridine **3a** with thiophenol in the presence of K_2CO_3 in toluene at 90 °C, and the ring-opening product **4a** was obtained in 95% yield as a single regioisomer (Scheme 2).^{8h}

The compound 4a was subjected to C–N cyclization with copper powder (1.0 equiv) in DMF at 120 °C for 8 h, and indole 5a was obtained in 65% yield along with indoline 6a in 25% yield (Table 1, entry 1). To find out the optimized reaction conditions for the exclusive formation of 5a, the ring-opening product 4a was subjected to C–N cyclization and subsequent aromatization with different Cu catalysts and ligands. The optimization results are summarized in Table 1. The best result was obtained with a super stoichiometric amount of copper powder (2.0 equiv) in DMF at 120 °C (Table 1, entry 4), where the expected product 5a was obtained in 85% yield as the only product. It is worth mentioning that thiophenol was recovered back completely during column chromatographic purification of the indole product 5a.

To establish our strategy as a practical and useful general synthetic methodology for this purpose, a one-pot (stepwise) protocol for the synthesis of indole 5a from 3a was explored. When aziridine 3a was treated with PhSH, followed by Cu powder under the reaction conditions as shown in Scheme 3, the expected indole 5a was obtained in 82% yield.

To demonstrate the scope of our strategy, it was further extended for the synthesis of 2-methyl indole **5b** from the ringopening of an inseparable mixture (1:1) of *cis* and *trans* isomers of 2-(2-bromophenyl)-3-methyl-1-tosylaziridine **3b** with thio-

Received: September 26, 2015



Figure 1. Indole core structure containing commercial drugs and natural products.

Scheme 1. Proposed Reaction Pathway



Scheme 2. Regioselective Ring-Opening of 3a



Table 1. Optimization Study



^{*a*}All reactions were carried out with **4a** (0.2 mmol), *N*,*N*-dimethylformamide (DMF) (1.0 mL), in solvent under an argon atmosphere. ^{*b*}CuI (10 mol %), L₁, L₂, and L₃ (20 mol %), K₂CO₃ (1.0 equiv). L₁ = (\pm)-*trans*-1,2-diaminocyclohexane, L₂ = L-proline, L₃ = ethylenediamine.

Scheme 3. Synthesis of Indole 5a



phenol at 90 °C in toluene. Under the optimized conditions, when aziridine **3b** was reacted, only 50% of the starting material

was found to be consumed after 12 h. The reaction was continued for another 12 h; however, no further progress of the reaction could be noted. We could isolate the ring-opening product **4b** along with the unreacted aziridine **3b** as a pure *cis* isomer¹² (Scheme 4). *Trans* disubstituted aziridines are more





reactive than the *cis* isomer due to steric reasons, and under basic conditions, only the *trans* isomer reacted and the *cis* isomer was recovered completely.

To overcome this problem, we explored the LA (Lewis acid)catalyzed ring-opening of aziridines (as a mixture of both *cis* and *trans* isomers) with thiophenol. Various Lewis acids were screened for the ring-opening of aziridine **3b** (1:1 mixture of *cis* and *trans* isomers) with thiophenol, and the results are shown in Table 2. The best result was obtained with BF₃·OEt₂ (15 mol %) in CH₂Cl₂ for 2 h, and the ring-opening product **4b** was obtained in 94% yield with dr 4:1 (Table 2, entry 2). LAcatalyzed ring-opening of disubstituted aziridines by thiophenol follows an S_N2-pathway. Under acidic conditions, starting from aziridine **3b** (trans/*cis* 1:1), the ring-opening product **4b** was obtained with enhanced dr (*trans/cis* 4:1) in 94% yield. The



Sb	$\frac{1}{M} \frac{1}{M} \frac{PhSH, Lewis acid}{CH_2Cl_2}$ Br cis-trans(1:1)		SPh Me NHTs ar
entry	Lewis acids	time (h)	yield (%)
1	BF ₃ ·OEt ₂ (10 mol %)	3	90
2	BF ₃ ·OEt ₂ (15 mol %)	2	94
3	Cu(OTf) ₂ (15 mol %)	24	65
4	Sc(OTf) ₃ (15 mol %)	24	67
5	$Zn(OTf)_2$ (15 mol %)	24	55

Note

observed enhanced diastereoselectivity of **4b** is probably due to epimerization of the benzylic carbon center from the unreacted *cis* isomer of **3b** during the reaction. This could be possible as the epimerization would lead to the formation of the more stable *trans* isomer of **3b**.

Next, we intended to apply both the optimization conditions (Tables 1 and 2) for the one-pot synthesis of 2-methyl indole **5b** from aziridine **3b**. To our great pleasure, the strategy worked well and the expected product **5b** was obtained in 73% yield (Scheme 5).

Scheme 5. Synthesis of 2-Methyl Indole 5b



Encouraged by this result, the reactions of several disubstituted aziridines (as a mixture of *cis* and *trans* isomers) and several monosubstituted aziridines with thiophenol,

followed by copper powder-mediated C–N cyclization/ aromatization, were studied, and the corresponding 2-alkyl indoles 5a,c-p were obtained with good yields (Table 3). It is needless to mention that, in all the cases, thiophenol was recovered back completely.

For wider applicability of our protocol in terms of substrate scope, indole functionalized with a carbethoxy group at the 2-position (10) was synthesized from ethyl 3-(2-chlorophenyl)-1-tosylaziridine-2-carboxylate in good yield (Scheme 6).

Scheme 6. Synthesis of 2-Ethyl Carboxylate Indole 10



We believe that the copper powder-mediated C–N cyclization follows our earlier proposed mechanism.^{8h} Most probably, the final aromatization step follows Cu(I)-mediated

Table 3. Synthesis of 2-Alkyl Indoles and Indoles Derivatives

		Ts N	1. Ph	SH, BF ₃ .C DCM, rt,	0Et ₂ (15 mol ⁹ 15 min-2 h	%)			
		Y	^R 2. C	u powder MF, 120-1	(2.0 equiv) 25 °C, 8-24	h Ts			
		∽ Х За,с-р		yield up to	86%	5а,с-р			
entry	2-halo-aziridines 3 (mixture of <i>cis</i> and <i>trans</i>)	Product 5	Time (h)	Yield (%)	entry	2-halo-aziridines 3 (mixture of <i>cis</i> and <i>trans</i>)	Product 5	Time (h)	Yield (%)
1	Ts N Et Br 3c	Et 5c	22	70	9	Ts n-Pr Cl Cl 3k	CI N 5k Ts	24	64
2	Ts N n-Pr Br 3d	N n-Pr Ts 5d	20	67	10	Ts N	N 5a ^{Ts}	5	86
3	F Br 3e	F N Ts 5e	16	65	11	F Ts	F	16	80
4	F Br 3f	F N Sf	17	65	12			16	85
5	F Br 3g	F N Ts 5g	16	65	13	CI 3m	5m ^{Ts}	16	82
6	CI CI CI CI CI 3h	Cl N Ts 5h	21	70	14	CI CI 3n	CI Sn Ts	16	80
7	Cl Cl 3i	CI N 5i Ts	24	65	14		50 Ts	10	80
8	CI CI 3j	CI N 5j Ts	20	67	15	F Br 3p	F 5p Ts	8	81

desulfonylation via the formation of an intermediate cationic thioether species D (Scheme 7).¹³

Scheme 7. Plausible Mechanism



To conclude, we have developed a simple route to 2-alkyl indoles via regioselective ring-opening of 2,3-disubstituted aziridines with thiophenol, followed by copper powdermediated C–N cyclization and aromatization with good yields. It is needless to mention that our strategy is very simple, based on a C–N coupling step involving environmentally benign Cu powder without using any ligand or a base. We strongly believe that our described strategy can be used as an alternate general methodology for the synthesis of 2-alkyl indoles.

EXPERIMENTAL SECTION

General Experimental. Analytical thin-layer chromatography (TLC) was carried out using silica gel 60 F₂₅₄ precoated plates. Visualization was accomplished with a UV lamp or I2 stain. Silica gel 230-400 mesh size was used for column chromatography using the combination of ethyl acetate and petroleum ether as an eluent. Unless noted, all reactions were carried out in oven-dried glassware under an atmosphere of nitrogen using anhydrous solvents. Where appropriate, solvents and all reagents were purified prior to use following the guidelines of Perrin and Armarego¹⁴ and Vogel.¹⁵ Monosubstituted N-Ts aziridines and disubstituted N-Ts aziridines were prepared by following earlier reports.¹⁶ All styrenes were prepared by following earlier reports.¹⁷ All commercial reagents were used as received. IR spectra were recorded in potassium bromide (KBr) pellets. Proton nuclear magnetic resonance (¹H NMR) spectra were recorded at 400 and 500 MHz. Chemical shifts were recorded in parts per million (ppm, δ) relative to tetramethyl silane (δ 0.00). ¹Ĥ NMR splitting patterns are designated as singlet (s), doublet (d), double doublet (dd), triplet (t), quartet (q), or multiplet (m). Carbon nuclear magnetic resonance (¹³C NMR) spectra were recorded at 100 and 125 MHz. Mass spectra (MS) were obtained using FAB and ESI mass spectrometer (TOF). Melting points were determined using a hot stage apparatus and are reported as uncorrected.

 \tilde{N} -(2-(2-Bromophenyl)-2-(phenylthio)ethyl)-4-methyl-benzenesulfonamide (4a).^{8h} A solution of thiophenol (23 μ L, 0.22 mmol) in dry toluene (1.0 mL) was added dropwise at 90 °C to a stirred suspension of K₂CO₃ (1.1 equiv) in dry toluene (1.0 mL) under a nitrogen atmosphere. The reaction mixture was stirred at 90 °C for 5 min, and a solution of 2-(2-bromophenyl)-1-tosylaziridine 3a (71 mg, 0.2 mmol) in dry toluene (1.0 mL) was added dropwise over a period of 1 min at 90 °C. The reaction mixture was further stirred for 15 min at the same temperature. The reaction was monitored by TLC. It was cooled to room temperature, quenched with water, and extracted with ethyl acetate (3 \times 5.0 mL). The combined organic extract was washed with H_2O (3 × 5.0 mL) and brine (15.0 mL) and dried over anhydrous Na2SO4. The solvent was removed under reduced pressure to give the crude product, which was purified by flash column chromatography on silica gel (230-400 mesh) by using ethyl acetate in petroleum ether to afford the pure products as a thick liquid in 95% yield. R_f 0.52 (30% ethyl acetate in petroleum ether); IR $\nu_{\rm max}$

(neat, cm⁻¹): 3281, 3059, 2923, 2854, 1597, 1470, 1438, 1329, 1159, 1092, 1024, 813, 691, 663, 551; ¹H NMR (500 MHz, CDCl3) δ 2.42 (s, 3H) 3.30–3.36 (m, 1H), 3.42–3.47 (m, 1H), 4.65 (t, *J* = 7.4 Hz, 1H), 4.82 (t, *J* = 6.4 Hz, 1H), 7.08–7.15 (m, 2H), 7.18–7.25 (m, 5H), 7.52 (dd, *J* = 8.0, 1.3 Hz, 1H), 7.64 (d, *J* = 8.6 Hz, 2H); ¹³C NMR (125 MHz, CDCl₃) δ 21.7, 46.1, 51.2, 124.8, 127.2, 127.9, 128.1, 128.7, 129.1, 129.5, 129.9, 132.5, 132.9, 133.4, 136.8, 137.4, 143.6; HRMS (ESI) calcd for C₂₁H₂₁BrNO₂S₂ (M + H)⁺ 462.0197, found 462.0199.

N-(1-(2-Bromophenyl)-1-(phenylthio)propan-2-yl)-4-methylbenzenesulfonamide (4b). Obtained only *trans* isomer 4b in 47% yield under basic conditions: IR ν_{max} (neat, cm⁻¹): 3210, 3015 2923, 1594, 1560, 1478, 1376, 1228, 1185, 1163, 1093, 1051, 982, 910, 865, 815, 731, 690, 664, 576, 557; ¹H NMR (500 MHz, CDCl₃): δ 1.13 (d, J = 6.9 Hz, 3H), 2.36 (s, 3H), 3.83–3.90 (m, 1H), 4.75 (d, J = 4.6 Hz, 1H), 5.02 (d, J = 9.2 Hz, 1H), 7.04 (dd, J = 7.5, 1.6 Hz, 1H), 7.07–7.09 (m, 2H), 7.13–7.18 (m, SH), 7.20 (td, J = 7.5, 1.7 Hz, 1H), 7.45 (dd, J = 8.0, 1.2 Hz, 1H), 7.64 (dd, J = 7.5, 1.7 Hz, 1H), 7.69 (d, J = 8.6 Hz, 2H); ¹³C NMR (125 MHz,CDCl₃): δ 18.4, 21.6, 52.3, 58.4, 124.4, 126.9, 127.3, 127.7, 129.0, 129.2, 129.6, 130.2, 131.0, 133.0, 134.4, 138.0, 138.1, 143.3; HRMS (ESI) calcd for C₂₂H₂₆BrN₂O₂S₂ (M + NH₄)⁺ 493.0619, found 493.0618.

2-(2-Bromophenyl)-3-methyl-1-tosylaziridine (*cis*-**3b**). Recovered *cis* aziridine **3b** obtained in 45% yield: ¹H NMR (500 MHz, CDCl₃): δ 0.96 (d, *J* = 5.7 Hz, 3H), 2.44 (s, 3H), 3.26–3.31 (m, 1H), 3.96 (d, *J* = 7.5 Hz, 1H), 7.13 (td, *J* = 7.5, 2.3 Hz, 1H), 7.15–7.20 (m, 2H), 7.34 (d, *J* = 8.0 Hz, 2H), 7.50 (d, *J* = 7.5 Hz, 1H), 7.89 (d, *J* = 8.0 Hz, 2H); ¹3C NMR (125 MHz,CDCl₃): δ 12.1, 21.7, 41.9, 47.1, 123.1, 127.3, 128.0, 129.4, 129.9, 130.1, 132.3, 133.0, 135.3, 144.7; HRMS (ESI) calcd for C₁₆H₁₇BrNO₂S (M + H)⁺ 366.0163, found 366.0164.

General Procedure for the C–N Cyclization. Method A. To N-(2-(2-bromophenylthio)-2-phenylethyl)-4methylbenzenesulfonamide 4a (1.0 equiv) in dry DMF (2.0 mL) was added Cu powder (2.0 equiv). The reaction mixture was heated at 120 °C for 4 h, and the progress of the reaction was monitored by TLC. It was cooled to room temperature and quenched with water and extracted with ethyl acetate (3 × 5.0 mL). The combined organic extract was washed with H₂O (3 × 5.0 mL) and brine (30.0 mL) and dried over Na₂SO₄. The solvent was removed under reduced pressure, and the crude product was purified by flash column chromatography on silica gel (230–400 mesh) using ethyl acetate in petroleum ether to afford the pure product **5a** as a white solid.

1-Tosyl-1H-indole (**5***a*). The general method A described above was followed when **4a** (92.5 mg, 0.2 mmol) was reacted with Cu powder (25.4 mg 0.4 mmol). The reaction mixture was heated 120 °C for 4 h to afford **5a** (46.1 mg, 0.170 mmol) as a white solid in 85% yield: mp 80–82 °C; R_f 0.46 (5% ethyl acetate in petroleum ether); IR ν_{max} (KBr, cm⁻¹): 3143, 2924, 2853, 1735, 1597, 1527, 1493, 1445, 1371, 1306, 1290, 1262, 1204, 1187, 1174, 1130, 1091, 1018, 992, 879, 812, 769, 747, 723, 703, 678, 644, 537; ¹H NMR (400 MHz, CDCl₃): δ 2.31 (s, 3H), 6.63 (d, *J* = 3.6 Hz, 1H), 7.18–7.31 (m, 4H), 7.51(d, *J* = 7.8 Hz, 1H), 7.55 (d, *J* = 3.6 Hz, 1H), 7.75 (d, *J* = 8.2 Hz, 2H), 7.98 (d, *J* = 9.2 Hz, 1H); ¹³C NMR (125 MHz, CDCl₃): δ 21.6, 109.1, 113.6, 121.4, 123.3, 124.6, 126.4, 126.9, 129.9, 130.8, 134.9, 135.4, 145.0; HRMS (ESI) calcd for C₁₅H₁₃ NNaO₂S (M + Na)⁺ 294.0565, found 294.0569.

General Procedure for Regioselective the Ring-Opening of 2-(2-Bromophenyl)-3-methyl-1-tosylaziridine with Thiophenols. *Method B*. To a stirred solution of 3b (1.0 equiv) under a N₂ atmosphere in dry DCM (0.5 mL) was added thiophenol (1.0 equiv), followed by BF₃·OEt₂ (15 mol %). The reaction mixture was stirred at rt for 15 min-2 h. The reaction was monitored by TLC. After completion of the reaction mixture, it was quenched with water and extracted with ethyl acetate (3×5.0 mL). The combined organic extract was washed with H₂O (3×5.0 mL) and brine (15.0 mL) and dried over Na₂SO₄. The solvent was removed under reduced pressure to give the crude product, which was purified by flash column chromatography on silica gel (230–400 mesh) using ethyl acetate in petroleum ether to afford the pure products as a thick liquid.

N-(1-(2-Bromophenyl)-1-(phenylthio)propan-2-yl)-4-methylbenzenesulfonamide (4b). The general method B described above was followed when 3b (73.3 mg, 0.2 mmol) was reacted with thiophenol (20.4 μ L,0.2 mmol) in the presence of BF₃·OEt₂ (15 mol %) at rt for 2 h to afford 4b (92.4 mg, 0.188 mmol) as a thick liquid in 94% yield (dr 4:1): Rf 0.52 (20% ethyl acetate in petroleum ether); IR $\nu_{\rm max}$ (neat, cm⁻¹): 3270, 3059, 2925, 1597, 1480, 1461, 1438, 1380, 1331, 1161, 1092, 1023, 986, 907, 814, 738, 689, 670, 549; ¹H NMR $(400 \text{ MHz}, \text{CDCl}_3) \delta 1.12 (t, J = 6.9 \text{ Hz}, 3\text{H}), 1.20 (t, J = 6.4 \text{ Hz}, 3\text{H}),$ 2.35 (s, 3H), 2.39 (s, 3H), 3.70-3.75 (m, 1H), 3.82-3.90 (m, 1H), 4.74 (d, J = 4.9 Hz, 1H), 5.09 (d, J = 9.2 Hz, 1H), 6.98-7.08 (m, 5H), 7.13–7.15 (m, 6H), 7.18–7.21 (m, 3H), 7.43–7.45 (m, 3H), 7.61–765 (m, 4H), 7.68–7.69 (m, 2H); $^{13}\mathrm{C}$ NMR (125 MHz,CDCl₃) δ 18.3, 20.5, 21.6, 52.3, 58.4, 124.4, 126.9, 127.1, 127.3, 127.5, 127.6, 127.7, 129.1, 129.3, 129.6, 130.1, 131.0, 131.8, 133.0, 134.4, 138.0, 138.0, 143.3; HRMS (ESI) calcd for C₂₂H₂₆BrN₂O₂S₂ (M + NH₄)⁺ 493.0619, found 493.0618.

General Procedure for a One-Pot Protocol for the Synthesis of 2-Alkyl Indole. *Method C*. To a stirred solution of aziridine (1.0 equiv) under a N₂ atmosphere in dry DCM (0.5 mL) was added thiophenol (1.0 equiv), followed by BF₃·OEt₂ (15 mol %). The reaction mixture was stirred at rt for 0.15–2 h. Cu powder (2.0 equiv) and DMF were added, and the mixture was heated to 120–125 °C for 8–24 h. The reaction was monitored by TLC. It was cooled to room temperature and quenched with water and extracted with ethyl acetate (3 × 5.0 mL). The combined organic extract was washed with H₂O (3 × 5.0 mL) and brine (5.0 mL) and dried over Na₂SO₄. The solvent was removed under reduced pressure to give the crude product, which was purified by flash column chromatography on silica gel (230–400 mesh) using ethyl acetate in petroleum ether to afford the pure products as white solids.

2-Methyl-1-tosyl-1H-indole (**5b**). The general method C described above was followed when **3b** (73.2 mg, 0.2 mmol) was reacted with thiophenoxide [(20.4 μL, 0.20 mmol), BF₃·OEt₂ (3.8 μL, 0.03 mmol)] at rt for 2 h, followed by treatment with Cu powder (2.0 equiv) and 2 mL of DMF at 120 °C for 22 h to afford **5b** (41.7 mg, 0.146 mmol) as a thick liquid in 73% yield; R_f 0.53 (5% ethyl acetate in petroleum ether); IR ν_{max} (KBr, cm⁻¹): 2926, 1596, 1452, 1367, 1294, 1240, 1218, 1187, 1174, 1150, 1091, 1052, 1022, 1001, 913, 810, 747, 704, 690, 659, 632, 583, 543; ¹H NMR (500 MHz, CDCl₃): δ 2.33 (s, 3H), 2.59 (s, 3H), 6.33 (s, 1H), 7.18–7.20 (m, 3H), 7.23–7.26 (m, 1H), 7.49 (d, *J* = 8.0 Hz, 1H), 7.65 (d, *J* = 7.9 Hz, 2H), 8.15 (d, *J* = 8.6 Hz 1H); ¹³C NMR (100 MHz, CDCl₃): δ 15.9, 21.6, 109.6, 114.6, 120.0, 123.5, 123.8, 126.4, 129.8, 129.9, 136.4, 137.1, 137.4, 144.8; HRMS (ESI) calcd for C₁₆H₁₆NO₂S (M + H)⁺ 286.0902, found 286.0901.

2-Ethyl-1-tosyl-1H-indole (5c). The general method C described above was followed when 3c (76.0 mg, 0.2 mmol) was reacted with thiophenoxide [(20.4 μ L, 0.20 mmol), BF₃·OEt₂ (3.8 μ L, 0.03 mmol)] at rt for 2 h, followed by treatment with Cu powder (2.0 equiv) and 2 mL of DMF at 120 °C for 22 h to afford 5c (41.3 mg, 0.14 mmol) as a thick liquid in 70% yield; Rf 0.66 (5% ethyl acetate in petroleum ether); IR $\nu_{\rm max}$ (KBr, cm⁻¹): 3065, 2973, 2927, 1913, 1739, 1596, 1567, 1493, 1451, 1432, 1369, 1305, 1292, 1276, 1225, 1205, 1187, 1174, 1146, 1119, 1091, 1051, 1022, 986, 937, 905, 812, 747, 705, 694, 659, 626, 542, 492, 431; ¹H NMR (400 MHz, CDCl₃): δ 1.32 (t, J = 7.3 Hz, 3H), 2.31 (s, 3H), 2.96-3.03 (m, 2H), 6.37 (s, 1H), 7.15-7.18 (m, 3H), 7.20–7.26 (m, 1H), 7.40 (d, J = 6.8 Hz, 1H), 7.61 (d, J = 8.7 Hz, 2H), 8.16 (d, J = 8.2 Hz 1H); ¹³C NMR (125 MHz, CDCl₃): δ 13.0, 21.6, 22.4, 107.8, 114.8, 120.2, 123.5, 123.9, 126.3, 129.9, 136.4, 137.3, 143.9, 144.7; HRMS (ESI) calcd for $C_{17}H_{18}NO_2S$ (M + H)⁺ 300.1058, found 300.1055.

2-Propyl-1-tosyl-1H-indole (5d). The general method C described above was followed when 3d (78.9 mg, 0.2 mmol) was reacted with thiophenoxide [(20.4 μ L, 0.20 mmol), BF₃·OEt₂ (3.8 μ L, 0.03 mmol)] at rt for 2 h, followed by treatment with Cu powder (2.0 equiv) and 2 mL of DMF at 120 °C for 20 h to afford 5d (42.0 mg, 0.134 mmol) as a thick liquid in 67% yield; R_f 0.73 (10% ethyl acetate in petroleum ether); IR ν_{max} (KBr, cm⁻¹): 2927, 1594, 1451, 1366, 1219, 1173, 1144, 1118, 1090, 1050, 809, 745, 705, 688, 666, 577, 541; ¹H NMR (400 MHz, CDCl₃): δ 1.01 (t, J = 7.3 Hz, 3H), 1.77 (h, J = 7.4 Hz,

2H), 2.31 (s, 3H), 2.95 (t, J = 8.2 Hz, 2H), 6.36 (s, 1H), 7.15–7.18 (m, 2H), 7.20–7.25 (m, 2H), 7.38–7.40 (m, 1H), 7.60 (d, J = 8.3 Hz, 2H), 8.15 (d, J = 8.3 Hz 1H); ¹³C NMR (125 MHz, CDCl₃): δ 14.0, 21.6, 22.2, 108.8, 114.9, 120.1, 123.5, 123.8, 126.3, 129.8, 129.9, 136.3, 137.3, 142.4, 144.6; HRMS (ESI) calcd for C₁₈H₂₀NO₂S (M + H)⁺ 314.1215, found 314.1210.

5-*Fluoro-2-methyl-1-tosyl-1H-indole* (*5e*). The general method C described above was followed when **3e** (76.8 mg, 0.2 mmol) was reacted with thiophenoxide [(20.4 μL, 0.20 mmol)), BF₃·OEt₂ (3.8 μL, 0.03 mmol)] at rt for 2 h, followed by treatment with Cu powder (2.0 equiv) and 2 mL of DMF at 120 °C for 16 h to afford **5e** (39.4 mg, 0.13 mmol) as a thick liquid in 65% yield; R_f 0.61 (5% ethyl acetate in petroleum ether); IR ν_{max} (KBr, cm⁻¹): 2929, 2855, 1732, 1599, 1494, 1469, 1447, 1390, 1369, 1313, 1292, 1216, 1180, 1168, 1129, 1115, 1091, 1054, 1017, 1004, 958, 897, 859, 810, 778, 704, 684, 668, 635, 592, 566, 545, 494, 433; ¹H NMR (500 MHz, CDCl₃): δ 2.34 (s, 3H), 2.57 (s, 3H), 6.29 (s, 1H), 6.96 (td, *J* = 2.5, 9.2 Hz, 1H), 7.03 (dd, *J* = 2.5, 8.6 Hz, 1H), 7.20 (d, *J* = 8.0 Hz, 2H), 7.62 (d, *J* = 8.0 Hz, 2H), 8.08 (dd, *J* = 4.3, 8.6 Hz, 1H); ¹³C NMR (125 MHz, CDCl₃): δ 15.0, 15.8, 21.6, 105.5, 105.7, 109.4, 109.4, 111.5, 115.4, 115.5, 126.3, 129.9, 130.6, 130.7, 133.3, 136.1, 139.2, 144.9, 158.8, 160.7; HRMS (ESI) calcd for C₁₆H₁₅FNO₂S (M + H)⁺ 304.0808, found 304.0807.

2-Ethyl-5-fluoro-1-tosyl-1H-indole (5f). The general method C described above was followed when 3f (79.7 mg, 0.2 mmol) was reacted with thiophenoxide [(20.4 μ L, 0.20 mmol), BF₃·OEt₂ (3.8 μ L, 0.03 mmol)] at rt for 2 h, followed by treatment with Cu powder (2.0 equiv) and 2 mL of DMF at 120 °C for 17 h to afford 5f (41.2 mg, 0.13 mmol) as a thick liquid in 65% yield; R_f 0.62 (5% ethyl acetate in petroleum ether); IR $\nu_{\rm max}$ (KBr, cm $^{-1}$): 2974, 2928, 1597, 1493, 1468, 1448, 1370, 1306, 1267, 1230, 1210, 1189, 1179, 1156, 1131, 1117, 1091, 1055, 1017, 986, 958, 877, 860, 808, 778, 734, 703, 683, 663, 581, 557, 542; ¹H NMR (400 MHz, $CDCl_3$): δ 1.31 (t, J = 7.3 Hz, 3H), 2.33 (s, 3H), 2.96–3.01 (m, 2H), 6.33 (s, 1H), 6.95 (td, I = 2.3, 8.7 Hz, 1H), 7.05 (dd, J = 2.3, 8.7 Hz, 1H), 7.18 (d, J = 8.2 Hz, 2H), 7.58 (d, J = 8.5 Hz, 2H), 8.10 (dd, J = 4.6, 9.2 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃): δ 12.9, 21.6, 22.5, 105.7, 105.8, 107.6, 107.7, 111.4, 111.6, 115.7, 115.8, 126.3, 130.0, 130.9, 130.9, 133.6, 136.1, 144.9, 145.7, 158.8, 160.7; HRMS (ESI) calcd for C₁₇H₁₇FNO₂S (M + H)⁺ 318.0964, found 318.0969.

5-Fluoro-2-propyl-1-tosyl-1H-indole (5g). The general method C described above was followed when 3g (82.5 mg, 0.2 mmol) was reacted with thiophenoxide [(20.4 μ L, 0.20 mmol), BF₃·OEt₂ (3.8 μ L, 0.03 mmol)] at rt for 2 h, followed by treatment with Cu powder (2.0 equiv) and 2 mL of DMF at 120 °C for 16 h to afford 5g (43.1 mg, 0.13 mmol) as a thick liquid in 65% yield; R_f 0.66 (5% ethyl acetate in petroleum ether); IR $\nu_{\rm max}$ (KBr, cm $^{-1}$): 2963, 2873, 1693, 1597, 1466, 1449, 1369, 1266, 1209, 1189, 1179, 1157, 1116, 1091, 1053, 959, 859, 810, 780, 736, 711, 670, 616, 584, 573, 543; ¹H NMR (400 MHz, CDCl₃): δ 1.00 (t, J = 7.3 Hz, 3H), 1.76 (h, J = 7.3 Hz, 2H), 2.32 (s, 3H), 2.91–2.95 (m, 2H), 6.32 (d, J = 0.9 Hz, 1H), 6.95 (td, J = 2.8, 9.2 Hz, 1H), 7.04 (dd, J = 2.8, 8.7 Hz, 1H), 7.17 (d, J = 7.9 Hz, 2H), 7.56–7.59 (m, 2H), 8.08 (dd, J = 4.6, 9.2 Hz, 1H); ¹³C NMR (125 MHz, CDCl₃): δ 14.0, 21.7, 22.2, 31.2, 105.6, 105.8, 108.6, 108.7, 111.4, 111.6, 115.9, 116.0, 126.3, 129.9, 130.9, 131.0, 133.5, 136.0, 144.2, 144.9, 158.8, 160.8; HRMS (ESI) calcd for C₁₈H₁₈FNNaO₂S (M + Na)⁺ 354.0940, found 354.0949.

5-Chloro-2-methyl-1-tosyl-1H-indole (**5**h). The general method C described above was followed when **3h** (71.3 mg, 0.2 mmol) was reacted with thiophenoxide [(20.4 μL, 0.20 mmol), BF₃·OEt₂ (3.8 μL, 0.03 mmol)] at rt for 2 h, followed by treatment with Cu powder (2.0 equiv) and 2 mL of DMF at 125 °C for 21 h to afford **5h** (44.8 mg, 0.14 mmol) as a thick liquid in 70% yield; R_f 0.56 (5% ethyl acetate in petroleum ether); IR ν_{max} (KBr, cm⁻¹): 2925, 2853, 1596, 1441, 1370, 1305, 1239, 1217, 1174, 1151, 1132, 1090, 1072, 1003, 885, 808, 722, 672, 664, 600, 543; ¹H NMR (400 MHz, CDCl₃): δ 2.34 (s, 3H), 2.56 (s, 3H), 6.26 (s, 1H), 7.17–7.21 (m, 3H), 7.34 (d, *J* = 1.8 Hz, 1H), 7.62 (d, *J* = 8.7 Hz, 2H), 8.06 (d, *J* = 9.2 Hz, 1H); ¹³C NMR (125 MHz, CDCl₃): δ 15.8, 21.7, 108.9, 115.6, 119.6, 123.9, 126.4, 129.2, 130.0, 131.0, 135.4, 136.1, 139.0, 145.1; HRMS (ESI) calcd for C₁₆H₁₅CINO₂S (M + H)⁺ 320.0512, found 320.0513.

5-Chloro-2-propyl-1-tosyl-1H-indole (5i). The general method C described above was followed when 3i (76.8 mg, 0.2 mmol) was reacted with thiophenoxide [(20.4 μ L, 0.20 mmol), BF₃·OEt₂ (3.8 μ L, 0.03 mmol)] at rt for 2 h, followed by treatment with Cu powder (2.0 equiv) and 2 mL of DMF at 125 °C for 24 h to afford 5i (45.2 mg, 0.13 mmol) as a thick liquid in 65% yield; R_f 0.73 (5% ethyl acetate in petroleum ether); IR $\nu_{\rm max}$ (KBr, cm⁻¹): 2961, 2928, 2871, 1596, 1444, 1371, 1271, 1221, 1199, 1173, 1148, 1132, 1091, 1072, 1052, 871, 808, 738, 723, 689, 668, 601, 581, 543, 564; ¹H NMR (400 MHz, CDCl₃): δ 1.00 (t, I = 7.3 Hz, 3H), 1.75 (h, I = 7.3 Hz, 2H), 2.33 (s, 3H), 2.90-2.94 (m, 2H), 6.3 (d, J = 0.9 Hz, 1H), 7.17-7.19 (m, 3H), 7.35(d, J = 2.3 Hz, 1H), 7.56-7.59 (m, 2H), 8.07 (d, J = 9.6 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃): δ 14.0, 21.7, 22.1, 31.1, 108.1, 115.91, 119.7, 123.9, 126.3, 129.1, 129.2, 130.0, 131.2, 135.6, 136.0, 143.9, 145.0; HRMS (ESI) calcd for C₁₈H₁₉ClNO₂S (M + H)⁺ 348.0825, found 348.0817.

6-Chloro-2-ethyl-1-tosyl-1H-indole (5j). The general method C described above was followed when 3j (74.1 mg, 0.2 mmol) was reacted with thiophenoxide [(20.4 μ L, 0.20 mmol), BF₃·OEt₂ (3.8 μ L, 0.03 mmol)] at rt for 2 h, followed by treatment with Cu powder (2.0 equiv) and 2 mL of DMF at 125 °C for 20 h to afford 5j (44.7 mg, 0.13 mmol) as a thick liquid in 67% yield; R_f 0.62 (5% ethyl acetate in petroleum ether); IR ν_{max} (KBr, cm⁻¹): 3114, 2973, 2924, 1589, 1561, 1494, 1453, 1420, 1369, 1307, 1289, 1219, 1203, 1187, 1173, 1151, 1123, 1092, 1061, 1049, 1017, 988, 929, 866, 829, 811, 731, 703, 680, 661, 543, 490, 430; ¹H NMR (400 MHz, CDCl₃): δ 1.30 (t, J = 7.3Hz, 3H), 2.34 (s, 3H), 2.94-3.00 (m, 2H), 6.33 (s, 1H), 7.15-7.21 (m, 3H), 7.31 (d, J = 8.3 Hz, 1H), 7.60-7.63(m, 2H), 8.20 (d, J = 1.8 Hz, 1H); ¹³C NMR (125 MHz, CDCl₃): δ 12.8, 21.7, 22.3, 107.2, 114.9, 120.8, 124.1, 126.4, 128.3, 129.8, 130.1, 136.1, 137.6, 144.6, 145.1; HRMS (ESI) calcd for $C_{17}H_{17}CINO_2S$ (M + H)⁺ 334.0669, found 334.0668.

6-Chloro-2-propyl-1-tosyl-1H-indole (5k). The general method C described above was followed when 3k (76.8 mg, 0.2 mmol) was reacted with thiophenoxide [(20.4 μ L, 0.20 mmol), BF₃·OEt₂ (3.8 μ L, 0.03 mmol)] at rt for 2 h, followed by treatment with Cu powder (2.0 equiv) and 2 mL of DMF at 125 °C for 24 h to afford 5k (44.5 mg, 0.127 mmol) as a thick liquid in 64% yield; R_{f} 0.73 (10% ethyl acetate in petroleum ether); IR $\nu_{\rm max}$ (KBr, cm⁻¹): 3113, 2958, 2926, 2868, 1694, 1586, 1557, 1493, 1460, 1419, 1372, 1306, 1283, 1249, 1219, 1199, 1171, 1152, 1123, 1073, 1049, 1034, 1015, 948, 904, 859, 844, 823, 812, 741, 703, 663, 543 543; ¹H NMR (500 MHz, $CDCl_3$): δ 1.01 (t, J = 7.5 Hz, 3H), 1.74 (h, J = 7.5 Hz, 2H), 2.34 (s, 3H), 2.91 (t, J = 6.9 Hz, 2H), 6.33 (s, 1H), 7.16-7.18 (m, 1H), 7.20 (d, J = 8.0 Hz, 2H), 7.30 (d, J = 8.6 Hz, 1H), 7.61 (m, J = 8.6 Hz 2H), 8.19 (s, 1H); ¹³C NMR (125 MHz, CDCl₃): δ 14.0, 21.7, 22.1, 31.0, 108.2, 115.1, 120.8, 124.1, 126.2, 126.4, 128.4, 129.7, 130.1, 134.2, 136.1, 137.6, 137.6, 143.1, 145.0; HRMS (ESI) calcd for $C_{18}H_{18}CINNaO_2S$ (M + H)⁺ 370.0644, found 370.0642.

1-Tosyl-1H-indole (5a). The general method C described above was followed when 3a (71 mg, 0.2 mmol) was reacted with thiophenoxide [(20.4 μ L, 0.20 mmol), BF₃·OEt₂ (3.8 μ L, 0.03 mmol)] at rt for 15 min, followed by treatment with Cu powder (2.0 equiv) and 2 mL of DMF at 120 °C for 5 h to afford 5a (46.1 mg, 0.172 mmol) as a white solid in 86% yield: mp 80–82 °C; R_f 0.46 (5% ethyl acetate in petroleum ether);

4-*Fluoro-1-tosyl-1H-indole* (*5l*). The general method C described above was followed when **3l** (65.1 mg, 0.2 mmol) was reacted with thiophenoxide [(20.4 μL, 0.20 mmol), BF₃·OEt₂ (3.8 μL, 0.03 mmol)] at rt for 15 min, followed by treatment with Cu powder (2.0 equiv) and 2 mL of DMF at 125 °C for 16 h to afford **5l** (46.3 mg, 0.16 mmol) as a white solid in 80% yield: mp 72–74 °C; *R*_f 0.53 (5% ethyl acetate in petroleum ether); IR ν_{max} (KBr, cm⁻¹): 2924, 2854, 1626, 1583, 1527, 1486, 1430, 1375, 1307, 1289, 1248, 1208, 1182, 1165, 1145, 1127, 1089, 1052, 1029, 946, 812, 786, 751, 703, 688, 670, 580, 560, 546, 520; ¹H NMR (400 MHz, CDCl₃): δ 2.33 (s, 3H), 6.73 (dd *J* = 0.9, 3.9, Hz, 1H), 6.86–6.91 (m, 1H),7.19–7.25 (m, 3H), 7.52 (d, *J* = 3.6 Hz, 1H), 7.74–7.46 (m, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 21.7, 104.6, 108.5, 108.7, 109.6, 109.6, 119.9, 125.4, 125.5, 126.3,

126.9, 130.1, 135.0, 136.9, 137.0 145.3, 154.6, 157.2; HRMS (ESI) calcd for $C_{15}H_{13}$ FNO_2S (M + H)^+ 290.0651, found 290.0657.

5-Chloro-1-tosyl-1H-indole (5m). The general method C described above was followed when 3m (68.4 mg, 0.2 mmol) was reacted with thiophenoxide [(20.4 μL, 0.20 mmol), BF₃·OEt₂ (3.8 μL, 0.03 mmol)] at rt for 15 min, followed by treatment with Cu powder (2.0 equiv) and 2 mL of DMF at 125 °C for 16 h to afford 5m (52.0 mg, 0.17 mmol) as a white solid in 85% yield: mp 65–67 °C; R_f 0.46 (5% ethyl acetate in petroleum ether); IR ν_{max} (KBr, cm⁻¹): 2922, 2850, 1596, 1440, 1374, 1336, 1285, 1249, 1197, 1170, 1145, 1129, 1092, 991, 810, 762, 720, 669, 586, 538; ¹H NMR (400 MHz, CDCl₃): δ 2.33 (s, 3H), 6.57 (d, *J* = 3.7 Hz, 1H), 7.20–7.25 (m, 3H), 7.5 (d, *J* = 1.8 Hz, 1H), 7.56 (d, *J* = 3.6 Hz, 1H), 7.72 (d, *J* = 8.5 Hz, 2H), 7.89 (d, *J* = 8.9 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃): δ 21.7, 108.5, 114.6, 121.0, 124.9, 126.9, 127.8, 129.2, 130.1, 132.0, 133.2, 135.1, 145.3; HRMS (ESI) calcd for C₁₅H₁₃ClNO₂S (M + H)⁺ 306.0356, found 306.0350.

6-*Chloro-1-tosyl-1H-indole* (*5n*). The general method C described above was followed when **3n** (68.4 mg, 0.2 mmol) was reacted with thiophenoxide [(20.4 μL, 0.20 mmol), BF₃·OEt₂ (3.8 μL, 0.03 mmol)] at rt for 15 min, followed by treatment with Cu powder (2.0 equiv) and 2 mL of DMF at 125 °C for 16 h to afford **5n** (49.7 mg, 0.163 mmol) as a white solid in 82% yield: mp 102–104 °C; *R*_f 0.46 (5% ethyl acetate in petroleum ether); IR ν_{max} (KBr, cm⁻¹): 3141, 2919, 1723, 1596, 1523, 1493, 1454, 1423, 1374, 1306, 1267, 1203, 1188, 1172, 1138, 1092, 1018, 996, 899, 867, 812, 761, 714, 668, 609, 596, 578, 541, 525; ¹H NMR (500 MHz, CDCl₃): δ 2.34 (s, 3H), 6.60 (d, *J* = 3.68 Hz, 1H), 7.17–7.24 (m, 3H),7.41 (d, *J* = 8.2 Hz, 1H), 7.53 (d, *J* = 3.6 Hz, 1H), 7.75 (d, *J* = 10.6 Hz, 2H), 7.99 (d, *J* = 1.8 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃): δ 21.7, 108.8, 113.8, 122.2, 124.1, 126.9, 127.0, 129.3, 130.1, 130.7, 135.1, 135.2, 145.4; HRMS (ESI) calcd for C₁₅H₁₃ClNO₂S (M + H)⁺ 306.0356, found 306.0350.

4-*Chloro-1-tosyl-1H-indole* (*5o*). The general method C described above was followed when **3o** (68.4 mg, 0.2 mmol) was reacted with thiophenoxide [(20.4 μL, 0.20 mmol), BF₃·OEt₂ (3.8 μL, 0.03 mmol)] at rt for 15 min, followed by treatment with Cu powder (2.0 equiv) and 2 mL of DMF at 125 °C for 16 h to afford **5o** (49.1 mg, 0.16 mmol) as a white solid in 80% yield: mp 78–80 °C; R_f 0.6 (5% ethyl acetate in petroleum ether); IR ν_{max} (KBr, cm⁻¹): 2924, 2850, 1596, 1572, 1523, 1471, 1419, 1374, 1285, 1225, 1194, 1169, 1132, 1101, 1003, 896, 811, 753, 703, 678, 643, 626, 576, 542; ¹H NMR (500 MHz, CDCl₃): δ 2.33 (s, 3H), 6.74–6.82 (m, 1H), 7.18–7.29 (m, 4H), 7.58–7.64 (m, 1H), 7.74 (d, *J* = 7.4 Hz, 2H), 7.88–7.94 (m, 1H); ¹³C NMR (100 MHz, CDCl₃): δ 21.7, 107.2, 112.1, 123.2, 125.3, 126.6, 126.9, 129.6, 130.1, 135.1, 135.5, 145.4; HRMS (ESI) calcd for C₁₅H₁₃ClNO₂S (M + H)⁺ 306.0356, found 306.0350.

5-Fluoro-1-tosyl-1H-indole (5p). The general method C described above was followed when 3p (74.0 mg, 0.2 mmol) was reacted with thiophenoxide [(20.4 μ L, 0.20 mmol), BF₃·OEt₂ (3.8 μ L, 0.03 mmol)] at rt for 15 min, followed by treatment with Cu powder (2.0 equiv) and 2 mL of DMF at 120 °C for 8 h to afford 5p (49.7 mg, 0.163 mmol) as a white solid in 81% yield: mp 102–104 °C; R_f 0.54 (5% ethyl acetate in petroleum ether); IR $\nu_{\rm max}$ (KBr, $\rm cm^{-1})$: 3145, 2924, 1615, 1594, 1530, 1493, 1460, 1444, 1399, 1372, 1348, 1307, 1291, 1259, 1216, 1188, 1172, 1139, 1114, 1091, 1040, 1018, 996, 950, 857, 810, 799, 761, 721, 703, 674, 626, 613, 590, 541, 524, 491, 473, 429; ¹H NMR (500 MHz, CDCl₃): δ 2.33 (s, 3H), 6.60 (d, J = 3.4 Hz, 1H), 7.02 (td, J = 2.9, 9.2 Hz, 1H), 7.16 (dd, J = 2.9, 9.2 Hz, 1H), 7.21 (d, J = 8.0 Hz, 2H), 7.58 (d, J = 3.4 Hz, 1H), 7.66 (d, J = 8.6 Hz, 2H), 7.91 (dd, J = 4.6, 9.2 Hz, 1H); ¹³C NMR (125 MHz, CDCl₃): δ 21.7, 106.8, 107.0, 109.0, 109.1, 112.6, 112.8, 114.6, 114.7, 126.9, 128.1, 130.0, 131.3, 131.8, 135.1, 145.2, 158.7, 160.6; HRMS (ESI) calcd for $C_{15}H_{13}FNO_2S (M + H)^+$ 290.0651, found 290.0651.

Ethyl 1-Tosyl-1H-indole-2-carboxylate (10). The general method C described above was followed when 9 (76.0 mg, 0.2 mmol) was reacted with thiophenoxide [(20.4 μ L, 0.20 mmol), BF₃·OEt₂ (3.8 μ L, 0.03 mmol)] at rt for 2 h, followed by treatment with Cu powder (2.0 equiv) and 2 mL of DMF at 125 °C for 20 h to afford 10 (41.2 mg, 0.12 mmol) as a thick liquid in 60% yield; R_f 0.53 (5% ethyl acetate in petroleum ether); IR ν_{max} (KBr, cm⁻¹): 2924, 2854, 1742, 1626, 1583, 1527, 1486, 1430, 1375, 1307, 1289, 1248, 1208, 1182, 1165, 1145,

1127, 1089, 1052, 1029, 946, 812, 786, 751, 703, 688, 670, 580, 560, 546, 520; ¹H NMR (400 MHz, CDCl₃): δ 1.38 (t, *J* = 7.3 Hz, 3H), 2.35 (s, 3H), 4.39 (q, *J* = 7.3 Hz, 2H), 7.13 (d, *J* = 1.1 Hz, 1H), 7.23–7.27 (m, 3H), 7.38–7.43 (m, 1H), 7.54 (d, *J* = 8.3 Hz, 1H), 7.90 (d, *J* = 8.7 Hz, 2H), 8.309 (d, *J* = 9.2 Hz, 1H); ¹³C NMR (125 MHz, CDCl₃): δ 14.2, 21.7, 62.1, 115.5, 116.6, 122.5, 124.1, 127.0, 127.5, 128.3, 129.6, 131.9, 135.7, 138.2, 145.0, 161.5; HRMS (ESI) calcd for C₁₈H₁₈NO₄S (M + H)⁺ 344.0957, found 344.0955.

General Procedure for Preparation of Aziridines.¹⁶ To a mixture of styrene derivatives (230 mg, 1.329 mmol) and anhydrous Chloramine-T (375 mg, 1.329 mmol) in CH₃CN (10 mL) was added PTAB (101 mg, 0.265 mmol) at 25 °C. After vigorous stirring for 12 h, the reaction mixture was diluted with ethyl acetate (40 mL) and water (20 mL). The organic layer was separated and washed with brine (20 mL), followed by drying over MgSO₄. The solvent was removed under reduced pressure to give the crude product, which was purified by flash column chromatography on silica gel (60–120 mesh) using ethyl acetate in petroleum ether to afford the pure products as white solids in good to moderate yield.

2-(2-Bromophenyl)-3-methyl-1-tosylaziridine (**3b**). Obtained as a thick liquid in 68% yield with *cis/trans* ratio 1:1: R_f 0.45 (5% ethyl acetate in petroleum ether); IR ν_{max} (KBr, cm⁻¹): 2928, 1596, 1566, 1473, 1439, 1405, 1325, 1305, 1291, 1235, 1184, 1162, 1117, 1090, 1047, 1026, 985, 888, 815, 756, 710, 685, 589, 577, 552; ¹H NMR (400 MHz, CDCl₃) δ 0.96 (d, J = 5.5 Hz, 3H), 1.19 (d, J = 5.9 Hz, 3H), 2.42 (s, 3H), 2.43 (s, 3H), 2.71–2.75 (m, 1H), 3.96 (dd, J = 7.2 Hz, 1H), 3.97 (dd, J = 4.5 Hz, 1H), 6.82–6.84 (m, 1H), 7.05–7.18 (m, 5H), 7.20–7.35 (m, 4H), 7.46–7.50 (m, 2H), 7.86–7.89 (m, 4H); ¹³C NMR (100 MHz, CDCl₃) δ 12.1, 14.1, 21.7, 21.8, 41.9, 47.1, 49.0, 49.5, 123.0, 123.2, 127.3, 127.6, 128.0, 129.4, 129.7, 129.9, 130.0, 132.3, 132.9, 135.2, 135.6, 137.7, 144.3, 144.7; HRMS (ESI) calcd for C₁₆H₁₇ BrNO₂S (M + H)⁺ 366.0163, found 366.0164.

2-(2-Bromophenyl)-3-ethyl-1-tosylaziridine (**3c**). Obtained as a thick liquid in 71% yield with *cis/trans* ratio 1:1: R_f 0.48 (5% ethyl acetate in petroleum ether); IR ν_{max} (KBr, cm⁻¹): 2968, 1596, 1439, 1327, 1231, 1184, 1162, 1091, 1019, 939, 908, 814, 754, 677, 591, 576, 557; ¹H NMR (400 MHz, CDCl₃) δ 0.76 (t, J = 14.7 Hz, 3H), 0.97–1.06 (m, 1H), 1.22 (t, J = 7.8 Hz, 3H), 1.27–1.34 (m, 1H), 2.15–2.22 (m, 1H), 2.24–2.34 (m, 1H), 2.40 (s, 3H), 2.43 (s, 3H), 2.61–2.66 (m, 1H), 3.07–3.12 (m, 1H), 3.99–4.02 (m, 2H), 6.85–6.88 (m, 1H), 7.05–7.14 (m, 3H), 7.16–7.22 (m, 2H), 7.28 (d, J = 7.8 Hz, 2H), 7.33 (d, J = 8.7 Hz, 2H), 7.47–7.50 (m, 2H), 7.85 (d, J = 8.2 Hz, 2H), 7.89 (d, J = 8.2 Hz, 2H); ¹³C NMR (125 MHz, CDCl₃) δ 11.3, 12.6, 21.7, 22.2, 47.1, 48.0, 48.8, 55.3, 123.1, 123.3, 127.2, 127.3, 127.5, 127.6, 128.2, 129.3, 129.4, 129.7, 129.8, 129.9, 132.3, 132.4, 133.1, 135.1, 135.4, 137.7, 144.2, 144.7; HRMS (ESI) calcd for C₁₇H₁₉ BrNO₂S (M + H)⁺ 380.0320, found 380.0320.

2-(2-Bromophenyl)-3-propyl-1-tosylaziridine (3d). Obtained as a thick liquid in 65% yield with cis/trans ratio 1:1: Rf 0.51 (5% ethyl acetate in petroleum ether); IR ν_{max} (KBr, cm⁻¹): 2959, 1596, 1439, 1327, 1184, 1162, 1092, 1025, 917, 814, 758, 678, 592, 576, 546; ¹H NMR (400 MHz, CDCl₃) δ 0.76 (t, J = 7.36 Hz, 3H), 0.90–0.97 (m, 1H), 0.99 (t, J = 14.68 Hz, 3H), 1.18-1.33 (m, 4H), 1.62-1.71 (m, 2H), 2.08-2.17 (m, 1H), 2.24-2.35 (m, 1H), 2.40 (s, 3H), 2.43 (s, 3H), 2.66-2.70 (m, 1H), 3.15-3.19 (m, 1H), 3.99-4.02 (m, 2H), 6.85-6.88 (m, 1H), 7.05-7.10 (m, 2H), 7.11-7.14(m, 1H), 7.19 (d, J = 4.6 Hz, 2H), 7.28 (d, J = 8.7 Hz, 2H), 7.33 (d, J = 8.3 Hz, 2H), 7.46–7.50 (m, 2H), 7.84 (d, J = 8.7 Hz, 2H), 7.88 (d, J = 8.2 Hz, 2H); $^{13}\mathrm{C}$ NMR (125 MHz, CDCl_3) δ 13.7, 14.1, 20.3, 21.5, 21.7, 21.8, 28.7, 30.7, 46.5, 47.0, 48.9, 53.9, 123.1, 123.3, 127.2, 127.5, 127.6, 128.1, 129.4, 129.7, 129.8, 129.8, 132.3, 132.5, 133.2, 135.1, 135.4, 137.7, 144.2, 144.7; HRMS (ESI) calcd for C₁₈H₂₁ BrNO₂S (M + H)⁺ 394.0476, found 394.0474.

2-(2-Bromo-5-fluorophenyl)-3-methyl-1-tosylaziridine (**3e**). Obtained as a thick liquid in 58% yield with *cis/trans* ratio 1:4: R_f 0.43 (5% ethyl acetate in petroleum ether); IR ν_{max} (KBr, cm⁻¹): 3052, 2924, 2855, 1730, 1624, 1596, 1480, 1460, 1408, 1379, 1360, 1304, 1293, 1237, 1185, 1122, 1090, 1054, 1026, 1001, 943, 870, 847, 800, 813, 740, 705, 690, 658, 628, 583, 530; ¹H NMR (500 MHz, CDCl₃) δ 0.97 (d, J = 5.7 Hz, 3H), 1.89 (d, J = 5.7 Hz, 3H), 2.44 (s, 3H), 2.45

(s, 3H), 2.70–2.74 (m, 1H), 3.26–3.31 (m, 1H), 3.92 (d, J = 1.7 Hz, 1H), 3.92–3.94 (m, 2H), 6.56 (dd, J = 9.1, 2.8 Hz, 1H), 6.81 (td, J = 8.0, 2.8 Hz, 1H), 6.86 (td, J = 8.0, 2.8 Hz, 1H), 6.91 (dd, J = 9.1, 2.8 Hz, 1H), 7.33 (d, J = 8.0 Hz, 2H), 7.36 (d, J = 8.0 Hz, 2H), 7.44 (dd, J = 8.2, 4.5 Hz, 1H), 7.45–7.47 (m, 1H), 7.87–7.89 (m, 4H); ¹³C NMR (125 MHz, CDCl₃) 12.0, 14.0, 21.7, 42.1, 46.6, 48.8, 49.3, 114.7, 114.9, 116.5, 116.7, 117.1, 117.3, 127.5, 128.0, 130.0, 133.6, 133.7, 137.5, 137.9, 138.0, 144.6, 161.1, 163.0; HRMS (ESI) calcd for C₁₆H₁₆BrFNO₂S (M + H)⁺ 384.0069, found 384.0068.

2-(2-Bromo-5-fluorophenyl)-3-ethyl-1-tosylaziridine (3f). Obtained as a thick liquid in 65% yield with cis/trans ratio 1:1: Rf 0.46 (5% ethyl acetate in petroleum ether); IR ν_{max} (KBr, cm⁻¹): 3068, 2969, 2934, 2878, 1598, 1579, 1469, 1418, 1328, 1305, 1290, 1270, 1220, 1184, 1162, 1091, 1038, 1018, 957, 940, 904, 876, 850, 813, 736, 714, 695, 673, 607, 575, 564; ¹H NMR (500 MHz, CDCl₃): δ 0.77 (t, J = 7.4 Hz, 3H), 1.00–1.06 (m, 1H), 1.23 (t, J = 7.4, Hz, 3H), 1.28– 1.33 (m, 1H), 2.16-2.22 (m, 1H), 2.30-233 (m, 1H), 2.42 (s, 3H), 2.45 (s, 3H), 2.59-2.62 (m, 1H), 3.09-3.13 (m, 1H), 3.95 (d, J = 4.0 Hz, 1H), 3.99 (d, J = 7.4 Hz, 1H), 6.59 (dd, J = 9.1, 2.8 Hz, 1H), 6.80 (td, J = 8.0, 2.8 Hz, 1H), 6.85 (td, J = 8.6, 3.4 Hz, 1H), 6.96 (dd, J =9.1, 2.8 Hz, 1H), 7.31 (d, J = 8.0 Hz, 2H), 7.35 (d, J = 8.0 Hz, 2H), 7.44 (m, 2H), 7.86 (d, J = 8.0 Hz, 2H), 7.89 (d, J = 8.0 Hz, 2H); ¹³C NMR (1 MHz, CDCl₃): 11.2, 12.6, 20.1, 21.7, 21.8, 22.1, 114.4, 114.6, 116.5, 116.6, 116.7, 116.8, 117.1, 117.3, 127.4, 128.1, 129.4, 129.8, 129.9, 133.6, 133.7, 133.8, 134.9, 135.5, 135.6, 137.5, 137.8, 144.5, 144.9, 160.8, 161.1, 162.8, 163.1; HRMS (ESI) calcd for $C_{17}H_{18}BrFNO_{2}S (M + H)^{+}$ 398.0226, found 398.0229.

2-(2-Bromo-5-fluorophenyl)-3-propyl-1-tosylaziridine (3g). Obtained as a thick liquid in 67% yield with cis/trans ratio 1:1.4: Rf 0.48 (5% ethyl acetate in petroleum ether); IR ν_{max} (KBr, cm⁻¹): 2961, 2932, 2873, 1598, 1580, 1470, 1418, 1328, 1305, 1269, 1218, 1184, 1162, 1093, 1031, 1018, 957, 922, 866, 814, 716, 693, 675, 590, 575, 538; ¹H NMR (400 MHz, CDCl₂): δ 0.76 (t, I = 7.3 Hz, 3H), 0.91– 0.96 (m, 1H), 1.00 (t, J = 7.3 Hz, 3H), 1.16–1.29 (m, 2H), 1.58–1.70 (m, 3H), 2.07–2.17 (m, 1H), 2.23–2.33 (m, 1H), 2.41 (s, 3H), 2.44 (s, 3H), 2.62-2.66 (m, 1H), 3.14-3.19 (m, 1H), 3.95-3.97 (m, 2H), 6.58 (dd, J = 9.1, 3.2 Hz, 1H), 6.79 (td, J = 8.2, 3.2 Hz, 1H), 6.85 (td, J = 8.2, 3.2 Hz, 1H), 6.94 (dd, J = 9.1, 2.7 Hz, 1H), 7.30 (d, J = 8.2 Hz, 2H), 7.34 (d, J = 8.2 Hz, 2H), 7.42–7.46 (m, 2H), 7.85 (d, J = 8.2 Hz, 2H), 7.88 (d, J = 8.2 Hz, 2H); ¹³C NMR (125 MHz, CDCl₃): 13.7, 14.0, 20.3, 21.5, 21.7, 21.8, 28.6, 30.5, 46.4, 46.7, 48.2, 54.3, 114.4, 114.5, 116.5, 116.6, 116.7, 116.8, 117.0, 117.1, 117.3, 127.5, 128.1, 129.8, 129.9, 133.7, 133.7, 133.8, 134.9, 135.5, 135.6, 137.4, 137.7, 137.8, 144.5, 145.0, 160.8, 161.1, 162.7, 163.1; HRMS (ESI) calcd for $C_{18}H_{20}BrFNO_2S (M + H)^+$ 412.0382, found 412.0382.

2-(2,5-Dichlorophenyl)-3-methyl-1-tosylaziridine (**3h**). Obtained as a thick liquid in 62% yield with *cis/trans* ratio 1:2.8: R_f 0.42 (5% ethyl acetate in petroleum ether); IR ν_{max} (KBr, cm⁻¹): 2929, 1597, 1469, 1398, 1327, 1234, 1185, 1162, 1091, 1054, 987, 912, 858, 814, 748, 714, 685, 598, 568, 528; ¹H NMR (400 MHz, CDCl₃): δ 0.95 (d, J = 5.9 Hz, 3H), 1.86 (d, J = 5.9 Hz, 3H), 2.44 (s, 3H), 2.72–2.78 (m, 1H), 3.23–3.27 (m, 1H), 3.95–3.96 (m, 2H), 6.78 (d, J = 2.2 Hz, 1H), 7.11 (dd, J = 8.2, 2.2 Hz, 1H), 7.16–7.19 (m, 2H), 7.23–7.26 (m, 2H), 7.32 (d, J = 8.2 Hz, 2H), 7.36 (d, J = 7.8 Hz, 2H), 7.83–7.89 (m, 4H); ¹³C NMR (125 MHz, CDCl₃): 12.1, 139, 21.7, 21.8, 42.1, 44.3, 46.4, 49.0, 127.5, 127.6, 128.0, 129.2, 129.3, 129.8, 129.9, 130.3, 131.8, 132.8, 133.0, 133.1, 134.7, 135.6, 137.4, 144.6, 145.0; HRMS (ESI) calcd for C₁₆H₁₆Cl₂NO₂S (M + H)⁺ 356.0279, found 356.0279.

2-(2,5-Dichlorophenyl)-3-propyl-1-tosylaziridine (**3i**). Obtained as a thick liquid in 54% yield with *cis/trans* ratio 1:2: R_f 0.52 (5% ethyl acetate in petroleum ether); IR ν_{max} (KBr, cm⁻¹): 2960, 2932, 2873, 1597, 1494, 1467, 1398, 1329, 1305, 1291, 1256, 1230, 1185, 1162, 1120, 1092, 1054, 1019, 999, 925, 814, 760, 730, 694, 673, 637, 593, 570, 561, 529; ¹H NMR (500 MHz, CDCl₃): δ 0.75 (t, J = 7.3 Hz, 3H), 0.91–0.96 (m, 1H), 1.00 (t, J = 7.3 Hz, 3H), 1.14–1.28 (m, 3H), 1.57–1.66 (m, 2H), 2.04–2.13 (m, 1H), 2.21–2.30 (m, 1H), 2.42 (s, 3H), 2.44 (s, 3H), 2.65–2.69 (m, 1H), 3.11–3.16 (m, 1H), 3.97 (d, J = 4.1 Hz, 1H), 4.00 (d, J = 7.3 Hz, 1H), 6.80 (d, J = 2.3 Hz, 1H), 7.10 (dd, J = 8.6, 2.7 Hz, 1H), 7.15–7.21 (m, 2 H), 7.23–7.25 (m, 2H),

7.31 (d, J = 7.8 Hz, 2H), 7.35 (d, J = 7.8 Hz, 2H), 7.85 (d, J = 8.2 Hz, 2H), 7.88 (d, J = 7.8 Hz, 2H); ¹³C NMR (125 MHz, CDCl₃): 13.6, 14.0, 20.2, 21.4, 21.7, 21.8, 28.6, 30.5, 44.1, 45.8, 46.7, 53.8, 127.2, 127.6, 128.2, 129.2, 129.3, 129.6, 129.8, 129.9, 130.3, 130.4, 131.8, 132.8, 133.1, 133.4, 134.8, 135.6, 137.3, 144.6, 150.0; HRMS (ESI) calcd for $C_{18}H_{20}Cl_2NO_2S$ (M + H)⁺ 384.0592, found 384.0594.

2-(2,4-Dichlorophenyl)-3-ethyl-1-tosylaziridine (3j). Obtained as a thick liquid in 70% yield with cis/trans ratio 1:1: Rf 0.48 (5% ethyl acetate in petroleum ether); IR $\nu_{\rm max}$ (KBr, cm⁻¹): 2970, 2934, 2878, 1593, 1560, 1476, 1412, 1380, 1329, 1305, 1291, 1232, 1185, 1163, 1119, 1092, 1054, 1019, 940, 897, 866, 814, 782, 738, 715, 695, 673, 573, 563, 543; ¹H NMR (400 MHz, CDCl₃): δ 0.75 (t, J = 7.4 Hz, 3H), 1.01–1.07 (m, 1H), 1.19 (t, J = 7.4 Hz, 3H), 1.23–1.28 (m, 1H), 2.13-2.18 (m, 1H), 2.26-2.28 (m, 1H), 2.41 (s, 3H), 2.44 (s, 3H), 2.62–2.65 (m, 1H), 3.06–3.11 (m, 1H), 3.96 (d, J = 4.6 Hz, 1H), 4.00 (d, J = 7.4 Hz, 1H), 6.82 (d, J = 8.5 Hz, 1H), 7.05 (dd, J = 8.0, 1.7 Hz, 1H), 7.12-7.17 (m, 2H), 7.28-7.35 (m, 6H), 7.84 (d, J = 8.5 Hz, 2H), 7.88 (d, J = 8.0 Hz, 2H); ¹³C NMR (1 MHz, CDCl₃): 11.1, 12.4, 20.1, 21.8, 22.2, 44.4, 46.0, 47.9, 55.0, 127.1, 127.4, 127.5, 128.0, 128.2, 129.0, 129.7, 129.9, 130.2, 130.5, 132.5, 134.2, 134.3, 134.4, 134.9, 137.5, 144.4, 144.9; HRMS (ESI) calcd for C₁₇H₁₈Cl₂NO₂S (M + H)⁺ 370.0435, found 370.0438.

2-(2,4-Dichlorophenyl)-3-propyl-1-tosylaziridine (3k). Obtained as a thick liquid in 54% yield with cis/trans ratio 1:1: R_c 0.51 (5% ethyl acetate in petroleum ether); IR $\nu_{\rm max}$ (KBr, cm⁻¹): 2960, 2932, 2873, 1593, 1560, 1476, 1410, 1381, 1329, 1305, 1291, 1229, 1163, 1119, 1093, 1054, 1018, 997, 918, 897, 815, 762, 746, 717, 693, 594; ¹H NMR (400 MHz, $CDCl_3$): δ 0.75 (t, J = 7.3 Hz, 3H), 1.00 (t, J = 7.3 Hz, 3H), 1.16-1.23 (m, 4H), 1.60-1.66 (m, 2H), 2.03-2.13 (m, 1H), 2.21-2.30 (m, 1H), 2.41 (s, 3H), 2.43 (s, 3H), 2.65-2.30 (m, 1H), 3.12-3.17 (m, 1H), 3.97-3.99 (m, 2H), 6.81 (d, J = 8.7 Hz, 1H), 7.04 (dd, J = 1.8, 8.2 Hz, 1H), 7.13 (m, 2H), 7.27 (s, 1H), 7.29 (s, 1H), 7.31-7.36 (m, 4H), 7.82 (d, J = 8.2 Hz, 2H), 7.87 (d, J = 8.2 Hz, 2H); ¹³C NMR (100 MHz, CDCl₃): δ 13.7, 14.0, 20.2, 21.4, 21.7, 28.6, 30.6, 44.3, 46.0, 46.4, 53.6, 127.1, 127.4, 127.5, 128.0, 128.1, 129.0, 129.1, 129.7, 129.9, 130.5, 132.4, 134.2, 134.3, 134.4, 134.8, 137.5, 144.4, 144.9; HRMS (ESI) calcd for C₁₈H₂₀Cl₂NO₂S (M + H)⁺ 384.0592, found 384.0598.

2-(2-Chloro-6-fluorophenyl)-1-tosylaziridine (**3***I*). Obtained as a thick liquid in 62% yield: IR ν_{max} (neat, cm⁻¹): 3509, 3092, 2924, 2854, 1606, 1576, 1494, 1453, 1370, 1329, 1306, 1291,1244, 1185, 1117, 1162, 1093, 1039, 1019, 985, 918, 896, 815, 788, 772, 730, 712, 694, 666, 640, 576, 555, 475; ¹H NMR (400 MHz, CDCl3): δ 2.43 (s, 3H), 2.73 (d, *J* = 4.56 Hz, 1H), 3.02 (dd, *J* = 1.36, 7.32 Hz, 1H), 3.86 (dd, *J* = 4.60, 7.32 Hz, 1H), 6.86–6.91 (m, 1H), 7.10–7.20 (m, 2H), 7.33 (d, *J* = 7.8 Hz, 2H), 7.86–7.89 (m, 2H); ¹³C NMR (100 MHz,CDCl₃): δ 21.8, 33.5, 36.5, 114.7, 114.9, 120.8, 120.9, 125.6, 125.6, 128.5, 129.7, 130.2, 130.3, 134.7, 136.1, 136.1, 144.8, 160.7, 163.2; HRMS (ESI) calcd for C₁₅H₁₄ClFNO₂S (M + H)⁺ 326.0418, found 326.0413.

2-(2,5-Dichlorophenyl)-1-tosylaziridine (**3m**). Obtained as a thick liquid in 52% yield: R_f 0.52 (30% ethyl acetate in petroleum ether); IR ν_{max} (neat, cm⁻¹): 3067, 2924, 1596, 1563, 1493, 1469, 1398, 1373, 1330, 1306, 1292, 1257, 1228, 1186, 1163, 1138, 1109, 990, 919, 886, 849, 814, 732, 706, 691, 664, 604, 586, 562, 513, 456; ¹H NMR (500 MHz, CDCl₃): δ 2.24 (d, *J* = 4.00 Hz, 1H), 2.45 (s, 3H), 3.01 (d, *J* = 6.9 Hz, 1H), 3.99 (dd, *J* = 2.65, 6.9 Hz, 1H), 7.16–7.18 (m, 2H), 7.24–7.26 (m, 1H), 7.36 (d, *J* = 8.05 Hz, 2H), 7.89 (d, *J* = 8.00 Hz, 2H); ¹³C NMR (100 MHz,CDCl₃): δ 21.8, 36.0, 38.3, 127.6, 128.2, 129.4, 130.0, 130.4, 132.0, 133.2, 134.5, 135.0, 145.2; HRMS (ESI) calcd for C₁₅H₁₄Cl₂NO₂S (M + H)⁺ 342.0122, found 342.0121.

2-(2,4-Dichlorophenyl)-1-tosylaziridine (**3n**). Obtained as a thick liquid in 74% yield: IR ν_{max} (neat, cm⁻¹): 2923, 1594, 1560, 1478, 1376, 1228, 1185, 1163, 1093, 1051, 982, 910, 865, 815, 731, 690, 664, 576, 557; ¹H NMR (400 MHz, CDCl₃): δ 2.24 (d, J = 4.56 Hz, 1H), 2.43 (s, 3H), 3.01 (d, J = 7.32 Hz, 1H), 3.96 (dd, J = 4.12, 7.32 Hz, 1H), 7.09–7.15 (m, 2H), 7.32–7.35 (m, 3H), 7.85–7.88 (m, 2H); ¹³C NMR (100 MHz,CDCl₃): δ 21.8, 35.8, 38.5, 127.5, 128.2, 128.5, 129.2, 129.9, 131.9, 134.5, 134.5, 134.6, 145.1; HRMS (ESI) calcd for C₁₅H₁₄Cl₂NO₂S (M + H)⁺ 342.0122, found 342.0128.

2-(2,6-Dichlorophenyl)-1-tosylaziridine (**3o**). Obtained as a thick liquid in 45% yield: ¹H NMR (400 MHz, CDCl₃): δ 2.48 (s, 3H), 2.52 (d, *J* = 4.60 Hz, 1H), 3.11 (d, *J* = 7.32 Hz, 1H), 3.86 (dd, *J* = 4.56, 6.88 Hz, 1H), 7.11–7.15 (m, 1H), 7.21–7.23 (m, 2H), 7.33 (d, *J* = 8.28 Hz, 2H), 7.88–7.90 (m, 2H); ¹³C NMR (100 MHz,CDCl₃): δ 21.8, 35.1, 39.8, 128.7, 128.8, 129.7, 129.9, 130.6, 134.9, 136.2, 144.9.

2-(2-Bromo-5-fluorophenyl)-1-tosylaziridine (**3p**). Obtained as a thick liquid in 67% yield: ¹H NMR (400 MHz, CDCl₃): δ 2.22 (d, *J* = 4.16 Hz, 1H), 2.44 (s, 3H), 3.02 (d, *J* = 6.88 Hz, 1H), 3.94 (dd, *J* = 4.12, 7.32 Hz, 1H), 6.82–6.92 (m, 2H), 7.35 (d, *J* = 7.8 Hz, 2H), 7.44 (dd, *J* = 5.04, 8.68 Hz, 1H), 7.88 (d, *J* = 8.24 Hz, 2H); ¹³C NMR (100 MHz,CDCl₃): δ 21.8, 36.2, 40.8, 115.1, 115.3, 116.8, 117.0, 117.3, 128.2, 130.0, 133.8, 133.9, 134.5, 137.1, 137.2, 145.2, 161.1, 163.1

Ethyl 3-(2-Chlorophenyl)-1-tosylaziridine-2-carboxylate (9). Obtained as a thick liquid in 62% yield with cis/trans ratio 1:1: Rf 0.27 (10% ethyl acetate in petroleum ether); IR ν_{max} (KBr, cm⁻¹): 2982, 1749, 1596, 1477, 1444, 1370, 1337, 1292, 1197, 1163, 1090, 1035, 917, 814, 759, 707, 684, 597, 561; ¹H NMR (400 MHz, CDCl₃): δ 0.94 (t, J = 6.8 Hz, 3H), 1.34 (t, J = 7.2 Hz, 3H), 2.43 (s, 3H), 2.45 (s, 3H), 3.40 (d, J = 3.6 Hz, 1H), 3.75 (d, J = 7.2 Hz, 1H), 3.91-4.00 (m, 2H), 4.21 (d, J = 7.1 Hz, 1H), 4.28–4.37 (m, 2H), 4.65 (d, J = 3.6 Hz, 1H), 7.05 (dd, J = 7.7, 1.8 Hz, 1H), 7.13-7.17 (m, 2H), 7.18-7.22 (m, 1H), 7.23-7.26 (m, 1H), 7.27-7.33 (m, 5H), 7.36 (d, J = 8.6 Hz, 2H), 7.82 (d, J = 8.1 Hz, 2H), 7.92 (d, J = 8.1 Hz, 2H); ¹³C NMR (125 MHz, CDCl₃): 13.8, 14.1, 21.7, 21.8, 42.7, 44.0, 45.9, 46.7, 61.7, 62.6, 126.6, 126.9, 127.8, 128.1, 128.3, 128.9, 129.5, 129.7, 129.9, 130.1, 131.2, 133.5, 133.9, 134.7, 140.0, 144.6, 145.5, 164.4, 165.5; HRMS (ESI) calcd for $C_{18}H_{18}CINNaO_4S (M + Na)^+$ 402.0543, found 402.0549.

ASSOCIATED CONTENT

S Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.joc.5b02251.

NMR spectra for all the new compounds (PDF)

AUTHOR INFORMATION

Corresponding Author

*E-mail: mkghorai@iitk.ac.in. Fax: (+91)-512-2597436. Phone: (+91)-512-2597518.

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

M.S. and Y.N. thank CSIR, India, for a research fellowship, and M.K.G. is grateful to IIT-Kanpur and DST, India, for financial support for conducting this research.

REFERENCES

(1) Feniuk, W.; Humphrey, P. P. A. Drug Dev. Res. 1992, 26, 235.
(b) Kaushik, N. K.; Kaushik, N.; Attri, P.; Kumar, N.; Kim, C. H.; Verma, A. K.; Choi, E. H. Molecules 2013, 18, 6620. (c) Gul, W.; Hamann, M. T. Life Sci. 2005, 78, 442.

(2) For recent reviews on indole synthesis, see: (a) Patil, N. T.; Yamamoto, Y. Chem. Rev. 2008, 108, 3395. (b) Higuchi, K.; Kawasaki, T. Nat. Prod. Rep. 2007, 24, 843. (c) Humphrey, G. R.; Kuethe, J. T. Chem. Rev. 2006, 106, 2875. (d) Cacchi, S.; Fabrizi, G. C. Chem. Rev. 2005, 105, 2873. (e) Gribble, G. W. J. Chem. Soc., Perkin Trans. 1 2000, 1045. (f) Bandini, M.; Eichholzer, A. Angew. Chem., Int. Ed. 2009, 48, 9608. (g) Cacchi, S.; Fabrizi, G. Chem. Rev. 2011, 111, PR215. (h) Patureau, F. W.; Glorius, F. Angew. Chem., Int. Ed. 2011, 50, 1977. (i) Shiri, M. Chem. Rev. 2012, 112, 3508.

(3) Robinson, B. *The Fisher Indole Synthesis*; Wiley-Interscience: New York, 1982.

(4) (a) Vieira, T. O.; Meaney, L. A.; Shi, Y.-L.; Alper, H. Org. Lett. 2008, 10, 4899. (b) Wang, C.; Huang, Y. Org. Lett. 2013, 15, 5294.

(c) Xiao, X.; Chen, T.-Q.; Ren, J.; Chen, W.-D.; Zeng, B.-B. *Tetrahedron Lett.* 2014, 55, 2056. (d) Yamagishi, M.; Nishigai, K.; Ishii, A.; Hata, T.; Urabe, H. *Angew. Chem., Int. Ed.* 2012, 51, 6471.
(e) Newman, S. G.; Lautens, M. J. Am. Chem. Soc. 2010, 132, 11416.
(f) Pan, Y.-Y.; Wu, Y.-N.; Chen, Z.-Z.; Hao, W.-J.; Li, G.; Tu, S.-J.; Jiang, B. J. Org. Chem. 2015, 80, 5764. (g) Liang, Y.; Yu, K.; Li, B.; Xu, S.; Song, H.; Wang, B. Chem. Commun. 2014, 50, 6130. (h) Zhu, C.; Ma, S. Org. Lett. 2013, 15, 2782.

(5) 2-Alkyl indoles synthesis, see: (a) Cajaraville, A.; Lopez, S.; Varela, J. A.; Saa, C. Org. Lett. 2013, 15, 4576. (b) Gong, T.-J.; Cheng, W.-M; Su, W.; Xiao, B.; Fu, Y. Tetrahedron Lett. 2014, 55, 1859.
(c) Nallagonda, R.; Rehan, M.; Ghorai, P. Org. Lett. 2014, 16, 4786.
(d) Ambrogio, I.; Cacchi, S.; Fabrizi, G. Tetrahedron Lett. 2007, 48, 7721. (e) Gschwend, H. W.; Rodriguez, H. R. Heteroatom-Facilitated Lithiations in Organic Reactions 1979, 26, 1–360 and references therein. (f) Jiao, L.; Bach, T. J. Am. Chem. Soc. 2011, 133, 12990.

(6) Azirines to indoles references; see: (a) Li, X.; Du, Y.; Liang, Z.; Li, X.; Pan, Y.; Zhao, K. Org. Lett. 2009, 11, 2643. (b) Taber, D. F.; Tian, W. J. Am. Chem. Soc. 2006, 128, 1058. (c) Novikov, M. S.; Khlebnikov, A. F.; Rostovskii, N. V.; Tcyrulnikov, S.; Suhanova, A. A.; Zavyalov, K. V.; Yufit, D. S. J. Org. Chem. 2015, 80, 18. (d) Candito, D. A.; Lautens, M. Org. Lett. 2010, 12, 3312. (e) Jana, S.; Clements, M. D.; Sharp, B. K.; Zheng, N. Org. Lett. 2010, 12, 3736. (f) Wendling, L. A.; Bergman, R. G. J. Org. Chem. 1976, 41, 831. (g) Nair, V.; Kim, K. H. J. Org. Chem. 1975, 40, 3784.

(7) Ghorai, M. K.; Nanaji, Y. J. Org. Chem. 2013, 78, 3867.

(8) Ring-opening of aziridines with sulfur nucleophiles; see references: (a) Zeng, F.; Alper, H. Org. Lett. 2010, 12, 5567. (b) Karikomi, M.; D'hooghe, M.; Verniest, G.; De Kimpe, N. Org. Biomol. Chem. 2008, 6, 1902. (c) D'hooghe, M.; Rottiers, M.; Kerkaert, I.; De Kimpe, N. Tetrahedron 2005, 61, 8746. (d) Cernerud, M.; Adolfsson, H.; Moberg, C. Tetrahedron: Asymmetry 1997, 8, 2655. (e) Concellón, J. M.; Bernad, P. L.; Suárez, J. R.; García-Granda, S.; Díaz, M. R. J. Org. Chem. 2005, 70, 9411. (f) Prasad, D. J. C.; Sekar, G. Org. Biomol. Chem. 2009, 7, 5091. (g) Alcaide, A.; Llebaria, A. J. Org. Chem. 2014, 79, 2993. (h) Ghorai, M. K.; Sayyad, M.; Nanaji, Y.; Jana, S. Chem. - Asian J. 2015, 10, 1480. (i) Ghorai, M. K.; Sahoo, A. K.; Bhattacharyya, A. J. Org. Chem. 2014, 79, 6468.

(9) (a) Minakata, S.; Okada, Y.; Oderaotoshi, Y.; Komatsu, M. Org. Lett. 2005, 7, 3509. (b) Ghorai, M. K.; Kumar, A.; Tiwari, D. P. J. Org. Chem. 2010, 75, 137. (c) Ghorai, M. K.; Das, K.; Shukla, D. J. Org. Chem. 2007, 72, 5859. (d) Ghorai, M. K.; Tiwari, D. P. J. Org. Chem. 2013, 78, 2617. (e) Stanković, S.; D'hooghe, M.; Catak, S.; Eum, H.; Waroquier, M.; Van Speybroeck, V.; De Kimpe, N.; Ha, H.-J. Chem. Soc. Rev. 2012, 41, 643. (f) Xing, S.; Ren, J.; Wang, K.; Cui, H.; Li, W.; Yan, H. Tetrahedron 2015, 71, 6290. (g) Wu, B.; Gallucci, J. C.; Parquette, J. R.; Rajanbabu, T. V. Chem. Sci. 2014, 5, 1102.

(10) Copper powder-catalyzed C-N cyclization references; see: (a) Wolf, C.; Liu, S.; Mei, X.; August, A. T.; Casimir, M. D. J. Org. Chem. 2006, 71, 3270. (b) Chen, Z.-G.; Wei, J.-F.; Li, R.-T.; Shi, X.-Y.; Zhao, P.-F. J. Org. Chem. 2009, 74, 1371. (c) Lee, H. K.; Cho, C. S. Synth. Commun. 2013, 43, 915. (d) Jiao, J.; Zhang, X.-R.; Chang, N.-H.; Wei, J.; Wang, J.-F.; Shi, X.-Y.; Chen, Z.-G. J. Org. Chem. 2011, 76, 1180. (e) Ghorai, M. K.; Shahi, C. K.; Bhattacharyya, A.; Sayyad, M.; Mal, A.; Wani, I. A.; Chauhan, N. Asian J. Org. Chem. 2015, 4, 1103. (11) Cu(I)-catalyzed C-N cyclization references; see: (a) Jiang, L. Molecules 2014, 19, 13448. (b) Xu, H.; Wolf, C. Chem. Commun. 2009, 3035. (c) Shafir, A.; Buchwald, S. L. J. Am. Chem. Soc. 2006, 128, 8742. (d) Mirallai, S. I.; Koutentis, P. A. J. Org. Chem. 2015, 80, 8329. (e) Ma, D. W.; Cai, Q.; Zhang, H. Org. Lett. 2003, 5, 2453. (f) He, C.; Chen, C.; Cheng, J.; Liu, C.; Liu, W.; Li, Q.; Lei, A. Angew. Chem., Int. Ed. 2008, 47, 6414. (g) Kong, L.; Zhou, Y.; Huang, H.; Yang, Y.; Liu, Y.; Li, Y. J. Org. Chem. 2015, 80, 1275. (h) Liu, H.; Duan, T.; Zhang, Z.; Xie, C.; Ma, C. Org. Lett. 2015, 17, 2932.

(12) Earlier, we reported that the *cis*-aziridines are less reactive toward S_N 2-type nucleophilic ring-opening compared to *trans*-aziridines, and under the present reaction conditions, *cis*-aziridines remained unreactive to thiophenol. (a) Ghorai, M. K.; Tiwari, D. P. J.

Org. Chem. **2010**, *75*, 6173. (b) Ghorai, M. K.; Shukla, D.; Bhattacharyya, A. J. Org. Chem. **2012**, *77*, 3740.

(13) (a) Cohen, T.; Herman, G.; Falck, J. R.; Mura, A. J., Jr. J. Org. Chem. 1975, 40, 812. (b) Cohen, T.; Kuhn, D.; Falck, J. R. J. Am. Chem. Soc. 1975, 97, 4749. (c) Cohen, T.; Mura, A. J.; Shull, D. W.; Fogel, E. R.; Ruffner, R. J.; Falck, J. R. J. Org. Chem. 1976, 41, 3218. (d) Cotton, F. A.; Wilkinson, Q. Advanced Inorganic Chemistry: A Comprehensive Text, 2nd ed.; John Wiley & Sons: New York, 1966; p 105.

(14) Perrin, D. D.; Armarego, W. L. F. In *Purification of Laboratory Chemicals*, 3rd ed.; Pergamon Press: Oxford, U.K., 1988.

(15) Furniss, B. S.; Hannaford, A. J.; Smith, P. W. G.; Tatchell, A. R. In *Vogel's Textbook of Practical Organic Chemistry*, 5th ed.; Longman Group: London, 1989.

(16) Jeong, J. U.; Tao, B.; Sagasser, I.; Henniges, H.; Sharpless, K. B. J. Am. Chem. Soc. **1998**, 120, 6844.

(17) Zhang, L., Jr.; Dolbier, W. R.; Sheeller, B.; Ingold, K. U. J. Am. Chem. Soc. 2002, 124, 6362.